Phase 4
Completed N=4
Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
Source: ClinicalTrials.gov NCT05209867 ↗Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcomePrimary: Number of Differentially Expressed Genes — 8.3 Differentially expressed genes
◆ Published Evidence
Emerging
11citations · ~6 / year
Oral Cannabidiol Treatment Is Associated with an Anti-Inflammatory Gene Expression Signature in Myeloid Cells of People Living with HIV.
Summary
People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH.
The investigators propose to study the effects of CBD on inflammation in PLWH, and establish the molecular role of different immune cells in this process. The investigators plan to use single cell RNA-sequencing (scRNAseq) to isolate CBD-specific cellular phenotypes from five persons with HIV who will provide blood samples before and after taking CBD.
Linked Publications
-
Oral Cannabidiol Treatment Is Associated with an Anti-Inflammatory Gene Expression Signature in Myeloid Cells of People Living with HIV.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Differentially Expressed Genes |
8.3 | — |
Eligibility Criteria
Inclusion Criteria
- Willingness to take CBD and to participate in follow up for two months
- Older than 21 and younger than 60
- Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count <350cells/ml)
Exclusion Criteria
- Conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis
- All medications that may affect inflammation such as aspirin, steroids, statins; CD4 count <350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)
- UF(University of Florida)/Shands staff and students will not be considered for enrollment
Data sourced from ClinicalTrials.gov (NCT05209867) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.